Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis
Image: Gilead, Galapagos announce 52-week results of filgotinib in FINCH 1, FINCH 3 studies in rheumatoid arthritis. Photo: courtesy of PublicDomainPictures from Pixabay.